{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:23Z","timestamp":1786982783421,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40273-018-0653-2","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T02:48:03Z","timestamp":1523933283000},"page":"853-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness Analysis of Crohn\u2019s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-\u03b1 Antagonist"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-4078","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Holko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-0597","authenticated-orcid":false,"given":"Andrzej","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS Souza de","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"653_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","volume":"52","author":"HC Chan","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52(2):141\u201350.","journal-title":"J Gastroenterol."},{"issue":"8","key":"653_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ecco-jcc\/jjv090","volume":"9","author":"DO Erim","year":"2015","unstructured":"Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB. The value of vedolizumab as rescue therapy in moderate-severe Crohn\u2019s disease patients with adalimumab non-response in the USA. J Crohns Colitis. 2015;9(8):669\u201375.","journal-title":"J Crohns Colitis."},{"issue":"6","key":"653_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14737167.2017.1322509","volume":"17","author":"F Rencz","year":"2017","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, et al. Cost-utility of biological treatment sequences for luminal Crohn\u2019s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):597\u2013606.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"2","key":"653_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/2050640617708952","volume":"6","author":"P Baji","year":"2018","unstructured":"Baji P, Gul\u00e1csi L, P\u00e9ntek M, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn\u2019s disease across Europe. United Eur Gastroenterol J. 2018;6(2):310\u201321.","journal-title":"United Eur Gastroenterol J."},{"issue":"4","key":"653_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40273-017-0593-2","volume":"36","author":"R Hodgson","year":"2018","unstructured":"Hodgson R, Walton M, Biswas M, et al. Ustekinumab for treating moderately to severely active Crohn\u2019s disease after prior therapy: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;36(4):387\u201398.","journal-title":"Pharmacoeconomics."},{"issue":"12","key":"653_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40273-016-0436-6","volume":"34","author":"R Rafia","year":"2016","unstructured":"Rafia R, Scope A, Harnan S, et al. Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2016;34(12):1241\u201353.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"653_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.5114\/aoms.2016.61915","volume":"12","author":"P Mo\u0107ko","year":"2016","unstructured":"Mo\u0107ko P, Kawalec P, Smela-Lipi\u0144ska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn\u2019s disease: a systematic review and meta-analysis. Arch Med Sci. 2016;12(5):1088\u201396.","journal-title":"Arch Med Sci."},{"issue":"34","key":"653_CR9","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3748\/wjg.v23.i34.6294","volume":"23","author":"M P\u00e9ntek","year":"2017","unstructured":"P\u00e9ntek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn\u2019s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294\u2013305.","journal-title":"World J Gastroenterol."},{"issue":"3","key":"653_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265\u201374.","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"653_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/apt.13276","volume":"42","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Mar\u00edn AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42(4):391\u2013405.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"653_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ajg.2016.569","volume":"112","author":"MJ Casanova","year":"2017","unstructured":"Casanova MJ, Chaparro M, Garc\u00eda-S\u00e1nchez V, et al. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol. 2017;112(1):120\u201331.","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"653_CR13","doi-asserted-by":"publisher","first-page":"e0168586","DOI":"10.1371\/journal.pone.0168586","volume":"11","author":"P Holko","year":"2016","unstructured":"Holko P, Kawalec P, Mossakowska M, Pilc A. Health-related quality of life impairment and indirect cost of Crohn\u2019s disease: a self-report study in Poland. PLoS One. 2016;11(12):e0168586.","journal-title":"PLoS One."},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B Ten Jonsson","year":"2009","unstructured":"Jonsson B Ten. Arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357\u20139.","journal-title":"Eur J Health Econ."},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/14737167.2014.957682","volume":"14","author":"M Marchetti","year":"2014","unstructured":"Marchetti M, Liberato NL. Biological therapies in Crohn\u2019s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res. 2014;14:815\u201324.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"653_CR16","unstructured":"European Medicines Agency. Summary of Product Characteristics: Entyvio, Stelara, Remicade, Remsima, Inflectra, Humira. www.ema.europa.eu . Accessed 19 Dec 2017."},{"issue":"4","key":"653_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/MEG.0000000000001047","volume":"30","author":"P Holko","year":"2018","unstructured":"Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012\u20132014: an analysis of nationwide databases. Eur J Gastroenterol Hepatol. 2018;30(4):456\u201364.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"653_CR18","unstructured":"The Agency for Health Technology Assessment and Tariff System. Health technology assessment guidelines. Version 3.0. www.aotm.gov.pl . Accessed 19 Dec 2017."},{"issue":"9317","key":"653_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet."},{"issue":"15","key":"653_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029\u201335.","journal-title":"N Engl J Med."},{"issue":"2","key":"653_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344\u201354.","journal-title":"Gastroenterology."},{"issue":"3","key":"653_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u201327.","journal-title":"Gastroenterology."},{"issue":"20","key":"653_CR23","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med."},{"issue":"16","key":"653_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328.","journal-title":"N Engl J Med."},{"issue":"1","key":"653_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97\u2013106.","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"653_CR26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med."},{"issue":"4","key":"653_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology. 1999;117(4):761\u20139.","journal-title":"Gastroenterology."},{"issue":"18","key":"653_CR28","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340(18):1398\u2013405.","journal-title":"N Engl J Med."},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333.","journal-title":"Gastroenterology."},{"key":"653_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829\u201338.","journal-title":"Ann Intern Med."},{"issue":"1\u20132","key":"653_CR31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.20452\/pamw.2638","volume":"125","author":"D Golicki","year":"2015","unstructured":"Golicki D, Niewada M. General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland. Pol Arch Med Wewn. 2015;125(1\u20132):18\u201326.","journal-title":"Pol Arch Med Wewn."},{"key":"653_CR32","unstructured":"Be Trade, spol. Ltd. LIEKinfo. www.liekinfo.sk . Accessed 28 Oct 2017."},{"key":"653_CR33","unstructured":"Narodowy Fundusz Zdrowia. Announcement from the Department of Medicinal Products, 27 September 2017. www.nfz.gov.pl . Accessed 19 Dec 2017."},{"issue":"1","key":"653_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","volume":"117","author":"MD Silverstein","year":"1999","unstructured":"Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49\u201357.","journal-title":"Gastroenterology."},{"key":"653_CR35","doi-asserted-by":"crossref","unstructured":"Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-\u03b1) inhibitors, adalimumab and infliximab, for Crohn\u2019s disease. Health Technol Assess. 2011;15(6).","DOI":"10.3310\/hta15060"},{"key":"653_CR36","unstructured":"Central Statistical Office of Poland. Life table, 2016. stat.gov.pl. Accessed 19 Dec 2017."},{"issue":"7","key":"653_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2036.2009.04228.x","volume":"31","author":"S Odes","year":"2010","unstructured":"Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn\u2019s disease patients by Markov analysis. Aliment Pharmacol Ther. 2010;31(7):735\u201344.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"653_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/cer-2017-0022","volume":"6","author":"P Kawalec","year":"2017","unstructured":"Kawalec P, Mo\u0107ko P, Malinowska-Lipien I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-\u03b1-refractory Crohn\u2019s disease patients: a systematic review and meta-analysis. J Comp Eff Res. 2017;6(7):601\u201312.","journal-title":"J Comp Eff Res."},{"issue":"2","key":"653_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MEG.0000000000001031","volume":"30","author":"P Holko","year":"2018","unstructured":"Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. Eur J Gastroenterol Hepatol. 2018;30(2):174\u201380.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"653_CR40","unstructured":"Central Statistical Office of Poland. Statistical Bulletins. www.stat.gov.pl. Accessed 19 Dec 2017."},{"key":"653_CR41","unstructured":"Narodowy Bank Polski (Central Bank of Poland). Weighted average rates of foreign currencies in PLN. nbp.pl. Accessed Dec 19, 2017."},{"issue":"1","key":"653_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s41669-016-0008-x","volume":"1","author":"P Holko","year":"2017","unstructured":"Holko P. Comment on: \u201cForecasting pharmaceutical prices for economic evaluations when there is no market: a review\u201d. PharmacoEconomics Open. 2017;1(1):69\u201370.","journal-title":"PharmacoEconomics Open."},{"issue":"2","key":"653_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0653-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:35:21Z","timestamp":1751553321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0653-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"17 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Przemys\u0142aw Holko, Pawe\u0142 Kawalec, and Andrzej Pilc declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"No direct funding was provided for the work performed. The research was undertaken as part of regular work at the Institute of Public Health. The research is part of the doctoral dissertation of P.H. The study was initiated by the researchers included as authors. No other persons had any influence on the work performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding and Roles"}},{"value":"All input data of the model are presented in the manuscript or the supplementary file. The model is available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}